Risk factors associated with non-remission/LDA in PsA pts: Baseline TJC>3, SJC>5 CRP>10 HAQ>0.5 enthesitis/dactylitis BMI>30 sDMARD use @RheumNow #EULAR2022 ABST#POS0080

Sex differences in PsA disease expression and treatment. Treatment efficacy and retention rates lower among female PsA pts initiating first TNFi. Women presented with higher 28 TJC and PRO at baseline as well.. @RheumNow #EULAR2022 ABST#POS0077 https://t.co/yV11kCN2bZ

Kristensen et al. 52 week results KEEPsAKE 1 RCT risankizumab vs PBO to week 24, then rescue, in csDMARD-IR PsA. ACR20 57% vs 34% (PBO) week 24, week 52 70%/63% ACR20. ACR 50/70 similar differences. PASI even better. @RheumNow #EULAR2022 POS1024 https://t.co/USQsMQ7oxu

Baseline molecular differences noted in PsA patients who are TNFi naive and incomplete responders. Elevated IL-22 expression may suggest increased involvement of IL-23 pathway in TNF-IR pts. @RheumNow #EULAR2022 ABST#POS0074

Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts. @RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC

Gordon et al. Long term safety IL23i risankizumab in psoriatic disease. Overall rates are consistent with those expected for PsO/PsA populations. @RheumNow #EULAR2022 POS1023 https://t.co/yv5fFbUSI6

Does MTX have an impact on UST-immunogenicity in PsA? Post-hoc analysis from UST RCT in 110+ pts No difference in ADA rates & concentrations between MTX and non-MTX groups and ADA not associated w/ decreased UST levels POS0079 @RheumNow #EULAR2022 https://t.co/TA0YTx8qRT

2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements across all key domains through 2 years of treatment @RheumNow #EULAR2022 POS1017 https://t.co/wcSKCID9Yt

☄️ Biomarkers substudies of COSMOS & DISCOVER-1 RCT GUS in PsA: TNFi-IR pts have a different plasma signature w/ higher BL IL-22 & TNF *Association between BL IL-22 levels & W24 PASI75 and trend for BL IL-22 levels & W24 ACR20 #EULAR2022 @RheumNow POS0074 @StefanSiebert1 https://t.co/Midtug4NJO

All the domains of sexual sphere are deteriorated in RA and PsA. This aspect is often overlooked and can have a significant impact on pts QoL. It may be time to assess this aspect more specifically using CSFQ-14 and propose dedicated interventions. #OP0139 @RheumNow #EULAR2022 https://t.co/l0zyBIZ1LI

The GESPIC cohort reports in Axial PsA, 75% had inflammatory back pain, 45% met NY criteria for AS, 55% with active inflammatory change in SI joint and 60% in the spine. This is where the overlap between Axial PsA and Axial SpA happens, Kading et al #EULAR2022 @RheumNow OP0026

🚨 Study on MTX and male fertility Analysis of semen parameters in 🙋🏼‍♂️HC 🙋🏼‍♂️RA, PsA and PsO MTX naive 🙋🏼‍♂️Post MTX Reassuring data as NO significant effect of MTX was observed on several semen parameters. #EULAR2022 @RheumNow OP0131 https://t.co/Fq32lzAMAx

Rahman et al. Pooled safety data from IL23i guselkumab clinical trial programme in PsA. 1508 patients 2125 PY. No increase (and generally lower) than PBO. No IBD. @RheumNow #EULAR2022 POS1015 https://t.co/9otcpwW9ni

Rahman et al shows factors associated with variability of fatigue in PsA are systemic disease 34%, joint disease 16%, skin involvement 12%, accounting for 62% and leaving a residual effeect of 38% that was unexplained and needing further research #EULAR2022 @RheumNow OP0025 https://t.co/RoqjS64Xjy